Payment overview · 2025
General Payments
$216.66
3 reported records · 2 companies
Healthcare provider profile · identity verified
Kimi Kay Guffey, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BRISTOL, TN · NPI 1023336708
Verified facts
What the public records show
CMS Open Payments records show Kimi Kay Guffey, NURSE PRACTITIONER received $216.66 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 91.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.71 | 91.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.95 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.66 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $197.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.41 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.41 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 172 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 138 | 44 |
| Lisinopril | Lisinopril | 137 | 41 |
| Pregabalin | Pregabalin | 112 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 106 | 33 |
| Clonazepam | Clonazepam | 105 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 96 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 33 |
| Losartan Potassium | Losartan Potassium | 79 | 25 |
| Metformin Hcl | Metformin Hcl | 77 | 21 |
| Trazodone Hcl | Trazodone Hcl | 73 | 26 |
| Omeprazole | Omeprazole | 72 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 23 |
| Diazepam | Diazepam | 63 | suppressed |
| Ondansetron Odt | Ondansetron | 63 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Promethazine Hcl | Promethazine Hcl | 54 | suppressed |
| Mounjaro | Tirzepatide | 53 | 12 |
| Furosemide | Furosemide | 52 | 17 |
| Eliquis | Apixaban | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 13 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 13 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 19 |
| Famotidine | Famotidine | 39 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Meloxicam | Meloxicam | 38 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 14 |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 16 |
| Azithromycin | Azithromycin | 36 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Montelukast Sodium | Montelukast Sodium | 36 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Atenolol | Atenolol | 32 | 12 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.66 · 3 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error